Cocrystal Pharma
COCP
16 hedge funds and large institutions have $1.01M invested in Cocrystal Pharma in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.38% more ownership
Funds ownership: 6.72% → 7.1% (+0.38%)
6% less funds holding
Funds holding: 17 → 16 (-1)
14% less capital invested
Capital invested by funds: $1.17M → $1.01M (-$160K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$31.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.51K |
| 4 |
Renaissance Technologies
New York
|
+$1.4K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$65 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.58K |
| 2 |
BlackRock
New York
|
-$494 |
| 3 |
Morgan Stanley
New York
|
-$9 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6 |
COCP Hedge Fund Activity: Q1 2024 in Review
16 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q1 2024, worth a combined $1.01M — down 14% from $1.17M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of COCP and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.
The largest buyer was UBS Group, adding an estimated $31.3K. The largest seller was JP Morgan Chase, cutting an estimated $2.58K.
- 16 institutional investors held Cocrystal Pharma (COCP) as of Q1 2024, down from 17 in Q4 2023.
- Funds reported $1.01M of Cocrystal Pharma stock for Q1 2024, down 14% quarter-over-quarter.
- 0 funds opened new Cocrystal Pharma positions in Q1 2024 and 1 closed out, a net change of -1 holder.
- The largest Cocrystal Pharma buyer in Q1 2024 was UBS Group, an estimated $31.3K added.
- The largest Cocrystal Pharma seller in Q1 2024 was JP Morgan Chase, an estimated $2.58K sold.
Based on aggregated 13F filings for Q1 2024.